These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8365641)

  • 1. Effect of ebrotidine on the synthesis and secretion of gastric sulfomucin.
    Slomiany BL; Lopez RA; Liau YH; Slomiany A
    Gen Pharmacol; 1993 May; 24(3):611-7. PubMed ID: 8365641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.
    Slomiany BL; Lopez RA; Slomiany A
    Biochem Int; 1992 Dec; 28(4):665-74. PubMed ID: 1482403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitecapone effect on the synthesis and secretion of gastric sulfomucin.
    Slomiany BL; Liau YH; Lopez RA; Slomiany A
    Gen Pharmacol; 1993 Jan; 24(1):69-73. PubMed ID: 8387047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori lipopolysaccharide effect on the synthesis and secretion of gastric sulfomucin.
    Liau YH; Lopez RA; Slomiany A; Slomiany BL
    Biochem Biophys Res Commun; 1992 May; 184(3):1411-7. PubMed ID: 1590801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.
    Slomiany BL; Piotrowski E; Piotrowski J; Zirvi KA; Liau YH; Murty VL; Slomiany A
    Gen Pharmacol; 1994 Sep; 25(5):1033-7. PubMed ID: 7835621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori aggregating activity of gastric mucin with ulcer healing by ebrotidine.
    Piotrowski J; Majka J; Piotrowski E; Murty VL; Gabryelewicz A; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1994 Nov; 34(5):875-81. PubMed ID: 7535617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of sulfation in the processing of gastric mucins.
    Liau YH; Murty VL; Slomiany A; Bielanski W; Slomiany BL
    J Physiol Pharmacol; 1991 Dec; 42(4):357-66. PubMed ID: 1726711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
    Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
    Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
    Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine.
    Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    Am J Gastroenterol; 1994 Jun; 89(6):894-7. PubMed ID: 8198101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.
    Slomiany BL; Piotrowski J; Mojtahed H; Slomiany A
    Gen Pharmacol; 1992 Mar; 23(2):203-6. PubMed ID: 1639232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: effect of ebrotidine.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1995 Nov; 26(7):1553-8. PubMed ID: 8690245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine.
    Slomiany BL; Piotrowski J; Slomiany A
    Scand J Gastroenterol; 1997 Jul; 32(7):638-42. PubMed ID: 9246701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of sulfation in post-translational processing of gastric mucins.
    Liau YH; Slomiany A; Slomiany BL
    Int J Biochem; 1992 Jul; 24(7):1023-8. PubMed ID: 1383042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ebrotidine on gastric mucosal calcium channel activity.
    Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
    Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide.
    Piotrowski J; Skrodzka D; Slomiany A; Slomiany BL
    Gen Pharmacol; 1997 May; 28(5):705-8. PubMed ID: 9184806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.